200 related articles for article (PubMed ID: 32544428)
1. CXCR4 antagonist AMD3100 (plerixafor): From an impurity to a therapeutic agent.
Wang J; Tannous BA; Poznansky MC; Chen H
Pharmacol Res; 2020 Sep; 159():105010. PubMed ID: 32544428
[TBL] [Abstract][Full Text] [Related]
2. Dual blockade of CXCL12-CXCR4 and PD-1-PD-L1 pathways prolongs survival of ovarian tumor-bearing mice by prevention of immunosuppression in the tumor microenvironment.
Zeng Y; Li B; Liang Y; Reeves PM; Qu X; Ran C; Liu Q; Callahan MV; Sluder AE; Gelfand JA; Chen H; Poznansky MC
FASEB J; 2019 May; 33(5):6596-6608. PubMed ID: 30802149
[TBL] [Abstract][Full Text] [Related]
3. Mozobil® (Plerixafor, AMD3100), 10 years after its approval by the US Food and Drug Administration.
De Clercq E
Antivir Chem Chemother; 2019; 27():2040206619829382. PubMed ID: 30776910
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxic drugs in combination with the CXCR4 antagonist AMD3100 as a potential treatment option for pediatric rhabdomyosarcoma.
Regenbogen S; Stagno MJ; Schleicher S; Schilbach K; Bösmüller H; Fuchs J; Schmid E; Seitz G
Int J Oncol; 2020 Jul; 57(1):289-300. PubMed ID: 32377699
[TBL] [Abstract][Full Text] [Related]
5. Molecular Pathways: Targeting the CXCR4-CXCL12 Axis--Untapped Potential in the Tumor Microenvironment.
Scala S
Clin Cancer Res; 2015 Oct; 21(19):4278-85. PubMed ID: 26199389
[TBL] [Abstract][Full Text] [Related]
6. Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100, Mozobil™) and potential of other CXCR4 antagonists as stem cell mobilizers.
De Clercq E
Pharmacol Ther; 2010 Dec; 128(3):509-18. PubMed ID: 20826182
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of CXCR4 and CXCR7 Is Protective in Acute Peritoneal Inflammation.
Ngamsri KC; Jans C; Putri RA; Schindler K; Gamper-Tsigaras J; Eggstein C; Köhler D; Konrad FM
Front Immunol; 2020; 11():407. PubMed ID: 32210974
[TBL] [Abstract][Full Text] [Related]
8. Clinical and genetic features of Warts, Hypogammaglobulinemia, Infections and Myelokathexis (WHIM) syndrome.
Dotta L; Tassone L; Badolato R
Curr Mol Med; 2011 Jun; 11(4):317-25. PubMed ID: 21506920
[TBL] [Abstract][Full Text] [Related]
9. Cytotoxic effects of chemokine receptor 4 inhibition by AMD3100 in biliary tract cancer cells: Potential drug synergism with gemcitabine.
Mayr C; Neureiter D; Pichler M; Berr F; Wagner A; Kiesslich T; Namberger K
Mol Med Rep; 2015 Aug; 12(2):2247-52. PubMed ID: 25846744
[TBL] [Abstract][Full Text] [Related]
10. CXCR4 antagonism sensitizes cancer cells to novel indole-based MDM2/4 inhibitors in glioblastoma multiforme.
Daniele S; La Pietra V; Piccarducci R; Pietrobono D; Cavallini C; D'Amore VM; Cerofolini L; Giuntini S; Russomanno P; Puxeddu M; Nalli M; Pedrini M; Fragai M; Luchinat C; Novellino E; Taliani S; La Regina G; Silvestri R; Martini C; Marinelli L
Eur J Pharmacol; 2021 Apr; 897():173936. PubMed ID: 33581134
[TBL] [Abstract][Full Text] [Related]
11. The CXCR4 antagonist plerixafor corrects panleukopenia in patients with WHIM syndrome.
McDermott DH; Liu Q; Ulrick J; Kwatemaa N; Anaya-O'Brien S; Penzak SR; Filho JO; Priel DA; Kelly C; Garofalo M; Littel P; Marquesen MM; Hilligoss D; Decastro R; Fleisher TA; Kuhns DB; Malech HL; Murphy PM
Blood; 2011 Nov; 118(18):4957-62. PubMed ID: 21890643
[TBL] [Abstract][Full Text] [Related]
12. CXCR4 inhibition with AMD3100 attenuates amphetamine induced locomotor activity in adolescent Long Evans male rats.
Mason B; Calhoun C; Woytowicz V; Pina L; Kanda R; Dunn C; Alves A; Donaldson ST
PLoS One; 2021; 16(3):e0247707. PubMed ID: 33647040
[TBL] [Abstract][Full Text] [Related]
13. Genetics on a WHIM.
Al Ustwani O; Kurzrock R; Wetzler M
Br J Haematol; 2014 Jan; 164(1):15-23. PubMed ID: 24111611
[TBL] [Abstract][Full Text] [Related]
14. Potential clinical applications of the CXCR4 antagonist bicyclam AMD3100.
De Clercq E
Mini Rev Med Chem; 2005 Sep; 5(9):805-24. PubMed ID: 16178723
[TBL] [Abstract][Full Text] [Related]
15. Subacute AMD3100 Treatment Is Not Efficient in Neonatal Hypoxic-Ischemic Rats.
Spiess DA; Campos RMP; Conde L; Didwischus N; Boltze J; Mendez-Otero R; Pimentel-Coelho PM
Stroke; 2022 Feb; 53(2):586-594. PubMed ID: 34794335
[TBL] [Abstract][Full Text] [Related]
16. Plerixafor on a WHIM - Promise or Fantasy of a New CXCR4 Inhibitor for This Rare, but Important Syndrome?
Merati N; Sivachandran S; Jfri A; Ben-Shoshan M; Vinh DC; Popradi G; Litvinov IV
Skin Therapy Lett; 2022 Mar; 27(2):1-5. PubMed ID: 35385630
[TBL] [Abstract][Full Text] [Related]
17. The CXCR4 antagonist plerixafor (AMD3100) promotes proliferation of Ewing sarcoma cell lines in vitro and activates receptor tyrosine kinase signaling.
Berning P; Schaefer C; Clemens D; Korsching E; Dirksen U; Potratz J
Cell Commun Signal; 2018 May; 16(1):21. PubMed ID: 29776413
[TBL] [Abstract][Full Text] [Related]
18. Effect of Anti-inflammatory Treatment with AMD3100 and CX
Michalettos G; Walter HL; Antunes ARP; Wieloch T; Talhada D; Ruscher K
Mol Neurobiol; 2021 Nov; 58(11):5876-5889. PubMed ID: 34417725
[TBL] [Abstract][Full Text] [Related]
19. The therapeutic potential of CXCR4 antagonists in the treatment of HIV.
Fujii N; Nakashima H; Tamamura H
Expert Opin Investig Drugs; 2003 Feb; 12(2):185-95. PubMed ID: 12556213
[TBL] [Abstract][Full Text] [Related]
20. The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100.
Murakami T; Kumakura S; Yamazaki T; Tanaka R; Hamatake M; Okuma K; Huang W; Toma J; Komano J; Yanaka M; Tanaka Y; Yamamoto N
Antimicrob Agents Chemother; 2009 Jul; 53(7):2940-8. PubMed ID: 19451305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
